Williams G M, Iatropoulos M J, Jeffrey A M
Department of Pathology, New York Medical College, Valhalla 10595, USA.
Toxicol Pathol. 2000 May-Jun;28(3):388-95. doi: 10.1177/019262330002800306.
To explore differences in mechanisms of carcinogenicity at low and high exposures, we have conducted a series of exposure-response studies of hepatocarcinogenesis in rats using 2 well-studied DNA-reactive carcinogens, 2-acetylaminofluorene and diethylnitrosamine. In these studies, we have used intraperitoneal injection or intragastric instillation to deliver exact doses during an initiation segment followed by phenobarbital as a liver tumor promoter to enhance manifestation of initiation. This protocol results in carcinogenicity comparable to that produced by lifetime exposure to the carcinogens. Our findings in these experiments provide evidence for the following: (a) formation of DNA adducts can be nonlinear, with a plateau at higher exposures; (b) cytotoxicity shows no-effect levels and is related to exposure; (c) compensatory hepatocyte proliferation shows no-effect levels and can be supralinear at high exposures; (d) formation of preneoplastic hepatocellular altered foci can show no-effect levels and appears supralinear at high exposures; (e) no-effect levels can exist for tumor development, and the exposure response can be supralinear. We interpret these findings to reflect thresholds for hepatocellular initiating effects of these carcinogens and exaggerated responses at high exposures attributable to cytotoxicity and compensatory hepatocyte proliferation. Such enhanced proliferation of hepatocytes harboring DNA damage likely results in an exaggerated yield of mutations in critical genes, leading to supralinear initiation of carcinogenesis. Thus, mechanisms differ between low and high exposures. Based on these observations, we suggest that linear extrapolation from high toxic exposures to postulated low-exposure effects of DNA-reactive carcinogens can yield overestimates. Such extrapolation must be supported by mechanistic information. The finding of no-effect levels provides a basis for understanding why low-level environmental exposures of humans to even DNA-reactive carcinogens may convey no cancer risk.
为了探究低剂量和高剂量暴露下致癌机制的差异,我们使用两种经过充分研究的DNA反应性致癌物——2-乙酰氨基芴和二乙基亚硝胺,对大鼠肝癌发生进行了一系列暴露-反应研究。在这些研究中,我们在启动阶段通过腹腔注射或灌胃给予精确剂量,随后使用苯巴比妥作为肝肿瘤促进剂以增强启动作用的表现。该方案产生的致癌性与终身暴露于致癌物所产生的致癌性相当。我们在这些实验中的发现为以下内容提供了证据:(a) DNA加合物的形成可能是非线性的,在较高暴露水平时会达到平台期;(b) 细胞毒性存在无效应水平,且与暴露有关;(c) 代偿性肝细胞增殖存在无效应水平,在高暴露时可能呈超线性;(d) 癌前肝细胞改变灶的形成存在无效应水平,在高暴露时呈超线性;(e) 肿瘤发生可能存在无效应水平,暴露反应可能呈超线性。我们将这些发现解释为反映了这些致癌物对肝细胞启动作用的阈值以及高暴露时由于细胞毒性和代偿性肝细胞增殖导致的夸大反应。这种携带DNA损伤的肝细胞增殖增强可能导致关键基因中突变产量的夸大,从而导致致癌作用的超线性启动。因此,低剂量和高剂量暴露的机制不同。基于这些观察结果,我们认为从高毒性暴露线性外推至DNA反应性致癌物假定的低暴露效应可能会高估风险。这种外推必须有机制信息的支持。无效应水平的发现为理解为什么人类即使低水平环境暴露于DNA反应性致癌物也可能不传达癌症风险提供了基础。